Skip to content

Public FDA record

Z-1395-2022: CereLink ICP Monitor; Catalog No. 826820, 826820P. Intracranial pressure monitor.

Recall record Z-1395-2022 for Integra LifeSciences Corp.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1395-2022
Company in FDA record
Integra LifeSciences Corp.
FDA classification date
Jul 22, 2022
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class I

Reason stated in the source

Integra has received complaints associated with ICP readings drifting to -50 mmHg (out-of-range) and may manifest an error message "sensor or extension cable failure!" The firm has found that this is caused by electrical interference from a component of the monitor's circuit board and from the environment.

Source facts

Action
A recall notification titled 1st NOTIFICATION - URGENT: VOLUNTARY MEDICAL DEVICE CORRECTION, dated June 22, 2022, was sent by mail. This communicated troubleshooting techniques if an out-of-range reading is encountered when utilizing the Codman CereLink System, while Integra finalized a root cause investigation. A second notification, dated August 23, 2022, for this recall states that Integra is now conducting a removal of Codman CereLink ICP Monitors. Customers are asked to discontinue use of affected devices as soon as possible and remove the devices from service. If an affected device is being used on a patient, continued use should only be determined by an individual risk-benefit analysis by the responsible attending clinician. If the recalled device continues to be used on a patient, the patient needs to be carefully monitored and ensure cable management. If a progressive decline in ICP readings is observed, use another monitoring system for continued patient case as soon as possible. Once patient care is complete, discontinue use of the monitor and remove it from service. As CereLink ICP Monitors are removed from use, a sales representative will facilitate the return of the affected monitor. Complete the Acknowledgement Form and return it to your Account Manager or email it to FCA3@integralife.com or Fax the form to 1-609-750-4220. Keep a copy of the recall notification for your records. Any questions, contact your Integra Account Manager, Clinical Specialist, or Technical Support at technical.support@integralife.com or by phone at 888-772-7378.
Initiated
2022-06-22
Root cause
Device Design
Distribution
Worldwide Distribution: US nationwide, Australia, New Zealand, Canada, Hong Kong, Pakistan, Georgia, Saudi Arabia, Israel, South Africa, United Arab Emirates, Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Ireland, Italy, Latvia, Lithuania, Netherlands, Norway, Portugal, Switzerland, Spain, Sweden, Slovakia, and United Kingdom.
Recall number
Z-1395-2022
Recall status
Open, Classified
CDRH record ID
194454
FDA classified
2022-07-22
Recall event number
90457

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗